Intercept Pharmaceuticals (NASDAQ:ICPT) Sets New 1-Year Low at $60.05

Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) hit a new 52-week low during trading on Monday . The company traded as low as $60.05 and last traded at $60.05, with a volume of 75335 shares changing hands. The stock had previously closed at $62.81.

A number of analysts have commented on ICPT shares. Wedbush set a $243.00 target price on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 5th. Raymond James reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, June 6th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $73.00 target price for the company in a report on Monday, July 15th. BidaskClub cut shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 26th. Finally, Wells Fargo & Co raised shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $90.02 target price for the company in a report on Thursday, May 2nd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and sixteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $142.00.

The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -5.49 and a beta of 1.33. The firm has a 50-day moving average of $74.15. The company has a debt-to-equity ratio of 19.41, a current ratio of 3.72 and a quick ratio of 3.72.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.57) by ($0.46). The firm had revenue of $52.25 million during the quarter, compared to the consensus estimate of $52.15 million. Intercept Pharmaceuticals had a negative return on equity of 617.23% and a negative net margin of 162.49%. The business’s revenue for the quarter was up 45.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.22) earnings per share. As a group, equities analysts anticipate that Intercept Pharmaceuticals Inc will post -10.05 earnings per share for the current year.

In other news, Director Luca Benatti purchased 1,200 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $83.50 per share, for a total transaction of $100,200.00. Following the completion of the transaction, the director now directly owns 7,556 shares in the company, valued at approximately $630,926. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Lisa Bright sold 595 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total transaction of $46,802.70. Following the transaction, the insider now owns 20,452 shares of the company’s stock, valued at approximately $1,608,754.32. The disclosure for this sale can be found here. Corporate insiders own 5.00% of the company’s stock.

Several large investors have recently modified their holdings of the stock. First Trust Advisors LP boosted its position in shares of Intercept Pharmaceuticals by 21.2% during the second quarter. First Trust Advisors LP now owns 1,093,108 shares of the biopharmaceutical company’s stock worth $86,979,000 after acquiring an additional 191,132 shares during the last quarter. Norges Bank bought a new position in shares of Intercept Pharmaceuticals during the fourth quarter worth $28,428,000. Altrinsic Global Advisors LLC boosted its position in shares of Intercept Pharmaceuticals by 1.1% during the first quarter. Altrinsic Global Advisors LLC now owns 280,904 shares of the biopharmaceutical company’s stock worth $31,422,000 after acquiring an additional 2,960 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Intercept Pharmaceuticals by 9.3% during the fourth quarter. Geode Capital Management LLC now owns 259,886 shares of the biopharmaceutical company’s stock worth $26,193,000 after acquiring an additional 22,059 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Intercept Pharmaceuticals during the first quarter worth $20,777,000. Hedge funds and other institutional investors own 76.25% of the company’s stock.

Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: What is the balance sheet?

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.